# A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

> **NCT00558636** · PHASE3 · TERMINATED · sponsor: **Bayer** · enrollment: 91 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Sorafenib + Paclitaxel + Carboplatin
- **DRUG:** Placebo + Paclitaxel + Carboplatin

## Key facts

- **NCT ID:** NCT00558636
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-09
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 91 (ACTUAL)
- **Why stopped:** Terminated early when the results from Study NCT00300885 showed an overall lack of efficacy in NSCLC and increased mortality in subjects with squamous subtype.
- **Last updated:** 2013-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00558636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00558636, "A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00558636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*